The Effects of TZD on Fat Metabolism and Insulin Sensitivity in GH-Replaced GHD Patients
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
In the present double blind, placebo-controlled, parallel study we evaluated the impact of 12 weeks thiazolidinedione (TZD) administration on basal and insulin-stimulated substrate metabolism in growth hormone-replaced adults with growth hormone deficiency.
| Condition | Intervention |
|---|---|
|
Growth Hormone Deficiency |
Drug: Pioglitazone |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Double-Blind Primary Purpose: Treatment |
| Official Title: | "Can Growth Hormone's Lipolytic and Insulin-Antagonistic Effects be Modified by Peroxisome Proliferator-Activated Gamma Agonists?" |
- Circulating FFA level
- FFA turnover
- Lipid oxidation
| Estimated Enrollment: | 20 |
| Study Start Date: | September 2004 |
| Study Completion Date: | March 2006 |
In human subjects GH (Growth Hormone) acutely antagonises the effects of insulin on glucose uptake in skeletal muscle and increases the hepatic glucose production of humans. This has clinical implications for patients with active acromegaly, in whom the prevalence of glucose intolerance and overt diabetes mellitus is increased. It is also of significance in relation to GH replacement therapy in GH-deficient adults not least when considering that a substantial proportion of these patients are insulin resistant in the GH-untreated state. There is evidence to indicate that the acute insulin antagonistic effects may be balanced with time by the favourable effects of GH on body composition and physical fitness, but the data are ambiguous. The mechanism underlying these effects of GH are not fully characterised, but there is experimental evidence of a causal linked to the concomitant stimulation of lipolysis, since GH-induced insulin resistance is partly abrogated when lipolysis is pharmacologically suppressed. This is noteworthy since elevated levels of free fatty acids (FFA) are also implicated in the pathogenesis of insulin resistance in patients with the metabolic syndrome and type 2 diabetes mellitus. Thiazolidinediones (TZDs) are insulin sensitizers which function as highaffinity agonists for the nuclear peroxisome-proliferator-activated receptor (PPAR) gamma, which improve insulin sensitivity in T2DM. PPAR gamma is a nuclear receptor expressed mainly in adipocytes, which activates the transcription of genes involved in lipid and glucose metabolism. Administration of TZD in T2DM enhances insulin-stimulated glucose uptake via mechanisms including a lowering of circulating FFA and a redistribution of fat away from hepatocytes and myocytes and into peripheral adipocytes. To our knowledge, the impact of TZDs on GH-induced insulin resistance has not previously been reported. Experimental data in human subjects on this issue are of potential importance not only in relation to patients with abnormal GH status, but also regarding our understanding of the pathogenesis of insulin resistance in general and the complex actions of PPAR gamma activation in particular.
Eligibility| Ages Eligible for Study: | 19 Years to 71 Years |
| Genders Eligible for Study: | Male |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Growth hormone replaced (minimum 6 months) growth hormone deficient men
- Age over 18 years
Exclusion Criteria:
- Ischemic coronary disease, defined by EF<0.6, former myocardial infarction, angina pectoris or actual treatment of cardiac insufficiency
- Actual or former malignancy, except intracranial neoplasia that caused the participants pituitary disease, provided that there was clinical evidence for permanent remission
- Blood donation within 6 months
- Excessive alcohol consumption
- Known allergic reaction from contents of test drug
- Radioactive radiation exposure in terms of treatment or study enrollment within one year
- Liver insufficiency
- Insulin treatment
Contacts and Locations| Denmark | |
| Medical Department M, The Medical Research Laboratories, Aarhus University Hospital | |
| Aarhus C, Denmark, 8000 | |
| Principal Investigator: | Jens OL Jorgensen, MD | University of Aarhus |
More Information
Publications:
| ClinicalTrials.gov Identifier: | NCT00459940 History of Changes |
| Other Study ID Numbers: | 20030288 |
| Study First Received: | April 12, 2007 |
| Last Updated: | April 12, 2007 |
| Health Authority: | Denmark: Danish Medicines Agency Denmark: Danish Dataprotection Agency |
Keywords provided by University of Aarhus:
|
Growth hormone Lipolysis Insulin resistance Pioglitazone Growth hormone replaced growth hormone deficient adults |
Additional relevant MeSH terms:
|
Dwarfism, Pituitary Endocrine System Diseases Insulin Resistance Dwarfism Bone Diseases, Developmental Bone Diseases Musculoskeletal Diseases Bone Diseases, Endocrine Hypopituitarism Pituitary Diseases Hypothalamic Diseases Brain Diseases |
Central Nervous System Diseases Nervous System Diseases Hyperinsulinism Glucose Metabolism Disorders Metabolic Diseases Hormones Pioglitazone Insulin Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Pharmacologic Actions Hypoglycemic Agents |
ClinicalTrials.gov processed this record on May 16, 2013